This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Wepon's sales subsidiary fined for abuse of dominance in China's bromhexine hydrochloride market

( November 18, 2020, 02:32 GMT | Official Statement) -- MLex Summary: Wepon Group Zhejiang Pharmaceutical Sales has been fined 2,241,754 yuan ($341,960), equivalent to 3 percent of its revenue for 2019, by the Zhejiang provincial Administration for Market Regulation for abusing its dominant position in the market for bromhexine hydrochloride. According to a penalty decision published late yesterday, the company required drug manufacturers that purchased the pharmaceutical ingredient from it to hand over all injectable bromhexine hydrochloride that they produced to be sold by the company. The penalty decision was dated Nov. 3, 2020.The statement follows and the penalty decision is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections